BioLineRx Ltd. Overview
Pro stress-test →BioLineRx is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The company's first approved product is APHEXDA® (motixafortide), with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, which is being developed and commercialized by Ayrmid Ltd. The company has transformed into 'BioLineRx 2.0', focusing on lean drug development while retaining solid tumor indication rights for motixafortide.
Strategic Profile
Pro stress-test →Through major licensing agreements with Ayrmid ($10M upfront + $87M potential milestones) and GloriaBio ($15M upfront + $250M potential milestones), BioLineRx secures non-dilutive capital. The ongoing CheMo4METPANC Phase 2b clinical trial of motixafortide in metastatic pancreatic cancer is led by Columbia University and supported by both Regeneron and BioLineRx. BioLineRx also established a joint venture with Hemispherian to develop GLIX1, a Phase 1-ready candidate for glioblastoma, a >$3.7 billion global addressable market.
Competitive Landscape
Pro stress-test →GLIX1 targets glioblastoma, a >$3.7 billion global market that has seen little innovation since the standard of care was developed in 2005. BioLineRx competes with larger oncology-focused biotech companies and stem cell mobilization developers. Its advantage lies in retained solid tumor rights for motixafortide, lean cost structure, and partnership-based model.
Industry Context
BioLineRx Ltd. operates in Biopharmaceutical - Oncology & Rare Diseases.
Key facts
Founded: 2003 · Headquarters: Hevel Modi'in, Israel · Market cap: $12M (May 2025 estimate)